NatureWise Biotech & Medicals Corporation (4732) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of NatureWise Biotech & Medicals Corporation stock TWD 11.33, price TWD 14.80, that is 23.4% below the price, quality 47 out of 100. Rating: overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 3, 2026.
How to read this chart
60‑month range 14.80 TWD – 48.28 TWD · fair‑value band 7.48 TWD – 14.17 TWD · the 14.80 TWD price screens above the 11.33 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 3, 2026.
Follow NatureWise Biotech & Medicals in your weekly email
Every Wednesday you see whether NatureWise Biotech & Medicals is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
NatureWise Biotech & Medicals Corporation engages in the research and development of Western medicine, Chinese medicine, and biotechnology in Taiwan. It offers LipoCol Forte, a capsule for hypercholesterolemia and hypertriglyceridemia; and green propolis and red yeast rice products.
Show moreShow less
The company was founded in 1990 and is headquartered in Taipei, Taiwan.
Stock analysis
NatureWise Biotech & Medicals Corporation (4732) currently trades at 14.80 TWD, while our model-based Fair Value estimate is 11.33 TWD, 23% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 91/100, which puts the data coverage at low.
Scenario range: 7.48 TWD (bear) to 14.17 TWD (bull), the price of 14.80 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 47/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
NatureWise Biotech & Medicals Corporation reported revenue of 177M TWD in FY2025 versus 250M TWD in FY2021, a compound −8.3%/yr. Reported net income was −92.3M TWD in FY2025.
Key figures
Market cap 714M TWD (≈ $21.7M) Micro · P/S ratio 4.30 · EPS (TTM) −2.76 TWD · Dividend yield 1.3% · Net margin −76.6% · Return on equity −26.8% · Return on assets (EBIT) −1.7% (5-year average) · Operating margin −106%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 8 out of 100 (low confidence).
What moves the price
The share trades about 39% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −23%, 4732 screens richer than that median.
Fair Value models
Bear7.48 TWDFair Value 11.33 TWDBull14.17 TWD
Price 14.80 TWD · Downside -23.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−21.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−8.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−10.4%
Start year 2020 (pandemic)
Revenue growth 9 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.3%
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
18.9% (2020) → −60.5% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare NatureWise Biotech & Medicals Corporation with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks
Beats the industry median on 5/9 measures
A mixed picture versus its industry peers.
Valuation
Quality Score47 · Above median
Fair Value upside−23.4% · Above median
Profitability
Return on assets−12.9% · Below median
Net margin (12 months)−76.6% · Bottom 25%
Operating margin (12 months)−106.4% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)−2.5% · Below median
Dividend yield (12 months)1.3% · Above median
Valuation Multiplesvs Biotechnology median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is NatureWise Biotech & Medicals Corporation (4732) overvalued or undervalued?
As of Nov 3, 2026, our model estimates a fair value of 11.33 TWD versus a price of 14.80 TWD, about 23% lower (overvalued).
What is the fair value of 4732?
Our model-based fair value for NatureWise Biotech & Medicals Corporation is 11.33 TWD (as of Nov 3, 2026), built from audited fundamentals. The current price: 14.80 TWD.
What is the quality score of 4732?
NatureWise Biotech & Medicals Corporation has a Quality Score of 47/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for NatureWise Biotech & Medicals Corporation (4732)?
Our model-based price target is the fair value of 11.33 TWD (as of Nov 3, 2026) from 1 valuation models. Cautious scenario 7.48 TWD, optimistic scenario 14.17 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the NatureWise Biotech & Medicals Corporation stock forecast for 2026?
Our models put fair value at 11.33 TWD, about 23% lower versus a price of 14.80 TWD (overvalued). Cautious scenario 7.48 TWD, optimistic scenario 14.17 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of NatureWise Biotech & Medicals Corporation (4732)?
NatureWise Biotech & Medicals Corporation reported trailing-twelve-month revenue of about 175M TWD (latest available figure, as of Nov 3, 2026).
Does NatureWise Biotech & Medicals Corporation pay a dividend?
NatureWise Biotech & Medicals Corporation currently shows a dividend yield of 1.31% relative to its recent price (as of Nov 3, 2026).
How much is the dividend of NatureWise Biotech & Medicals Corporation (4732)?
NatureWise Biotech & Medicals Corporation has a dividend yield of 1.3%.
What is the intrinsic value of NatureWise Biotech & Medicals Corporation (4732)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For NatureWise Biotech & Medicals Corporation it is 11.33 TWD per share (as of Nov 3, 2026), against a price of 14.80 TWD. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is NatureWise Biotech & Medicals Corporation stock overvalued or undervalued in 2026?
As of Nov 3, 2026, 4732 trades above its calculated fair value: price 14.80 TWD, fair value 11.33 TWD, a gap of about −23% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 4732?
No. The price is what the market pays today (14.80 TWD); the fair value is what the company's own numbers justify (11.33 TWD). For NatureWise Biotech & Medicals Corporation the two are 3.47 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is NatureWise Biotech & Medicals Corporation worth?
The market values NatureWise Biotech & Medicals Corporation at about 714M TWD (market capitalisation, as of Nov 3, 2026). Per share that is 14.80 TWD; our models calculate a fair value of 11.33 TWD per share.
What do the bullish and bearish scenarios say about 4732?
Our models span a range for NatureWise Biotech & Medicals Corporation: cautious scenario 7.48 TWD, base 11.33 TWD, optimistic 14.17 TWD per share (as of Nov 3, 2026, price 14.80 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of NatureWise Biotech & Medicals Corporation (4732)?
Balance-sheet figures for NatureWise Biotech & Medicals Corporation (as of Nov 3, 2026): return on equity −26.8%. They feed the Quality Score of 47/100, which measures business quality independently of the share price.
How far is 4732 from its 52-week high?
NatureWise Biotech & Medicals Corporation trades at 14.80 TWD, about 39% below its 52-week high of 24.10 TWD and at the low of 14.80 TWD (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 11.33 TWD is for.
Which stocks are comparable to NatureWise Biotech & Medicals Corporation?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is NatureWise Biotech & Medicals Corporation stock attractive at the current price?
The data as of Nov 3, 2026: price 14.80 TWD, calculated fair value 11.33 TWD (−23%), Quality Score 47/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 4732 calculated?
We run NatureWise Biotech & Medicals Corporation through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of 11.33 TWD builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. NatureWise Biotech & Medicals Corporation itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of NatureWise Biotech & Medicals Corporation (4732)?
The closing price on Nov 6, 2026 was 14.80 TWD. Our model-based fair value is 11.33 TWD, about 23% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with NatureWise Biotech & Medicals Corporation right now?
The price sits above even our optimistic bull case (14.17 TWD). The favourable scenario is already priced in. Weak quality (47/100) and above fair value at the same time, the margin of safety is missing on both counts. A fairly wide model range (7.48 TWD to 14.17 TWD) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of NatureWise Biotech & Medicals Corporation
How large is the market capitalisation of NatureWise Biotech & Medicals Corporation (4732)?
The market capitalisation of NatureWise Biotech & Medicals Corporation is 714M TWD (≈ $21.7M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of NatureWise Biotech & Medicals Corporation (4732)?
The price-to-sales ratio of NatureWise Biotech & Medicals Corporation is 4.30 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of NatureWise Biotech & Medicals Corporation (4732)?
Earnings per share at NatureWise Biotech & Medicals Corporation are −2.76 TWD. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of NatureWise Biotech & Medicals Corporation (4732)?
The dividend yield of NatureWise Biotech & Medicals Corporation is 1.3%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of NatureWise Biotech & Medicals Corporation (4732)?
The net margin of NatureWise Biotech & Medicals Corporation is −76.6% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of NatureWise Biotech & Medicals Corporation (4732)?
The return on equity (ROE) of NatureWise Biotech & Medicals Corporation is −26.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of NatureWise Biotech & Medicals Corporation (4732)?
On an EBIT basis the return on assets of NatureWise Biotech & Medicals Corporation is −1.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of NatureWise Biotech & Medicals Corporation (4732)?
The operating margin of NatureWise Biotech & Medicals Corporation is −106% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at NatureWise Biotech & Medicals Corporation (4732)?
Revenue at NatureWise Biotech & Medicals Corporation is growing −2.5% versus a year earlier (3y avg −8.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does NatureWise Biotech & Medicals Corporation (4732) generate?
The free cash flow of NatureWise Biotech & Medicals Corporation is −113M TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does NatureWise Biotech & Medicals Corporation (4732) hold?
NatureWise Biotech & Medicals Corporation holds more cash than debt, 316M TWD net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch NatureWise Biotech & Medicals Corporation in the live analysis
One click puts NatureWise Biotech & Medicals Corporation on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 3, 2026